April 25, 2024
Trial | EXCALIBER |
---|---|
Cancer Type | Haematological Cancers and Myeloma |
Hospital(s) | Belfast City Hospital |
Information | A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) |